Showing posts with label psychedelic. Show all posts
Showing posts with label psychedelic. Show all posts

Monday, 30 June 2014

More on the PsychonautWiki:About


From PsychonautWiki    Blogger Ref http://www.p2pfoundation.net/Multi-Dimensional_Science

Jump to: navigation, search

A high res version of the PsychonautWiki logo. Created by Josifikins
PsychonautWiki (PW) (previously known as Encyclopedia Psychonautica) is a community driven encyclopaedia which is working to establish psychonautics (the exploration of consciousness) as a legitimate field of science.
We aim to do this through producing a phenomenological breakdown, documentation and analysis of the consistent subjective effects found within a wide variety of our differing methodologies in an extremely high level of detail. The PW community has done this from a purely phenomenological perspective that does not depend on analogy, metaphors or mysticism to convey its definitions. The effects themselves are documented, organized and mapped out through the use of formal literary descriptions, terminologies and definitions which are organized into the separate articles below:
PsychonautWiki currently has 305 articles.

Mission statement

Our purpose here at PsychonautWiki includes:
  1. To establish psychonautics (the exploration of consciousness) as a legitimate field of science.
  2. To reach an understanding of consciousness through a phenomenological documentation and analysis of the consistent subjective effects found within its varying states.
  3. To minimize danger, maximize safety and end the cultural taboos associated with personal psychoactive substance usage by providing unbiased and scientifically accurate information.
  4. To provide a platform for the psychonaut community through which ongoing goal driven collaboration and discussion will be actively organized and encouraged.

History


PsychonautWiki on May the 12th 2013. Less than 24 hours after its creation.
PsychonautWiki was created to serve as a wider reaching, legitimate and community driven version of the blog known as DisregardEveryThingISay. This blog was originally formed on August the 22nd 2011[1] by Josifikins. It was created with the intention of mapping out the psychedelic experience in a satisfactory level of formal description that was seemingly non-existent within any of the current scientific literature.
As the website expanded and grew, it became increasingly obvious that tumblr was not going to be a suitable host for a project of this size. Thus on May the 11th 2013 PW was founded and the format of an open community driven wiki was chosen so that the project could progress as quickly as possible. This was done with the hopes that it would one day become entirely self-sufficient in its own momentum.
The wiki was not made public until August the 22nd 2013[2] when it was launched as an incomplete project still in beta mode. The full release of Version 1.0 remains in progress to this day but is quickly approaching completion.

The PW logo symbol was drawn by site founder Josifikins but was later improved upon and animated by a user known as Shpongulate. The original concept however was created by the late theoretical physicist John Archibald Wheeler on page 209 of his 1983 paper law withoutlaw. This symbol exists to serve as a visual representation of the most profound subjective effect component found within the entirety of the hallucinogenic experience which is known as a state of unity and interconnectedness. The eye represents the self and the line directly opposite represents that which it is perceiving within the "external" environment. The two sections are connected into each other via arrows to demonstrate that it is a singular and unified system.
  • Logo variations
  • Full size
  • Stare with text
  • Stare without text
  • Blink with text
  • Blink without text
  • Stoned with text
  • Stoned without text
  • Original depiction

Contributors

The PsychonautWiki project is run by a small team of extremely dedicated individuals each of which are mutually dependent upon the skills of one another and contribute their own specific and essential field of expertise. These are listed below in alphabetical order:
  • Caboose - In charge of assisting with general subjective effect documentation as well as content production, quality control and user moderation.
  • Cocoanatta - In charge of technical server operation, coding, website progression and maintenance, formal documentation, description and organization of PW's categorized subjective effects, and the overall development of psychonautics into an established field of science as well as general content production across the website.
  • DemFractalsYo - In charge of providing factual/accurate scientific information regarding the physical mechanisms behind the actions of psychoactive drugs, including but not limited to chemistry, pharmacology and neuroscience.
  • Josifikins - The original founder of PW and DEIS. In charge of the formal documentation, description and organization of PW's categorized subjective effects, general content production across the website and the overall development of psychonautics into an established field of science. This can be read about as a person within this community reddit interview found here.
  • Oscarette - In charge of editorial work such as grammar checking, quality control and editing as well as the formal documentation, description and organization of PW's categorized subjective effects, general content production across the website and the overall development of psychonautics into an established field of science.
  • PJosepherum - In charge of tripping absolute face, maintaining the server integrity, development and implementation of MediaWiki mods, content organisation and production, quality control, user moderation, et. cetera.
  • Replicatosaurus - In charge of the replication of the consistent subjective visual effects found within the hallucinogenic experience through the use of photography and image/video editing. Her work can be read about within this Huffington Post interview here.
  • Surgeon - In charge of semantics, managing templates, managing translations in all languages, translating the information found on PW in french as well as content production, quality control and user moderation.

References

  1. Jump up ↑ First post - Disregardeverythingisay | http://www.disregardeverythingisay.com/post/9252430368/disregard-everything-i-say
  2. Jump up ↑ http://www.disregardeverythingisay.com/post/59044473126/the-launch-of-a-new-website
at No comments:
Labels: , , , ,

Tuesday, 17 December 2013

Dimethyltryptamine (DMT)

 

From Wikipedia, the free encyclopedia
 
 
Jump to: navigation, search
Dimethyltryptamine
Systematic (IUPAC) name
2-(1H-indol-3-yl)-N,N-dimethylethanamine
Clinical data
Pregnancy cat. ?
Legal statusProhibited (S9) (AU) Schedule III (CA) CD Lic (UK) Schedule I (US)
RoutesOral (with an MAOI), Insufflated, Rectal, vaporized, IM, IV
Identifiers
CAS number61-50-7 N
ATC codeNone
PubChemCID 6089
IUPHAR ligand141
DrugBankDB01488
ChemSpider5864 YesY
UNIIWUB601BHAA YesY
KEGGC08302 YesY
ChEBICHEBI:28969 YesY
ChEMBLCHEMBL12420 YesY
Chemical data
FormulaC12H16N2 
Mol. mass188.269 g/mol
Physical data
Density1.099g/ml g/cm³
Melt. point40 °C (104 °F)
Boiling point160 °C (320 °F)
@ 0.6 Torr (80 Pa)[1]
also reported as
80–135 °C (176–275 °F)
@ 0.03 Torr (4.0 Pa)[2]
 N (what is this?)  (verify)
N,N-Dimethyltryptamine (DMT or N,N-DMT) is a psychedelic compound of the tryptamine family. Its presence is widespread throughout the plant kingdom.[3][4] DMT occurs in trace amounts in mammals, including humans, where it putatively functions as a trace amine neurotransmitter/neuromodulator.[5] It is originally derived from the essential amino acid tryptophan and ultimately produced by the enzyme INMT during normal metabolism.[6] The significance of its widespread natural presence remains undetermined. DMT is structurally analogous to the neurotransmitter serotonin (5-HT) and the hormone melatonin, and furthermore functionally analogous to other psychedelic tryptamines, such as 5-MeO-DMT, bufotenin, psilocin, and psilocybin.
When ingested, DMT acts as a psychedelic drug.[7] Depending on the dose and method of administration, its subjective effects can range from short-lived milder psychedelic states to powerful immersive experiences; these are often described as a total loss of connection to external reality and an experience of encountering indescribable spiritual/alien realms.[8] Indigenous Amazonian Amerindian cultures consume DMT as the primary psychoactive in ayahuasca, a shamanistic brew used for divinatory and healing purposes. Pharmacologically, ayahuasca combines DMT with an MAOI, an enzyme inhibitor that allows DMT to be orally active.[9]


History[edit]

DMT was first synthesized in 1931 by Canadian chemist Richard Helmuth Fredrick Manske (1901–1977).[10][11] Its discovery as a natural product is generally credited to Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima (1908–1989) who, in 1946, isolated an alkaloid he named nigerina (nigerine) from the root bark of jurema preta, that is, Mimosa tenuiflora.[11][12][13] However, in a careful review of the case Jonathan Ott shows that the empirical formula for nigerine determined by Gonçalves de Lima, which notably contains an atom of oxygen, can only match a partial, "impure" or "contaminated" form of DMT.[14] It was only in 1959, when Gonçalves de Lima provided American chemists a sample of Mimosa tenuiflora roots, that DMT was unequivocally identified in this plant material.[14][15] Less ambiguous is the case of isolation and formal identification of DMT in 1955 in seeds and pods of Anadenanthera peregrina by a team of American chemists led by Evan Horning (1916–1993).[14][16] Since 1955 DMT has been found in a host of organisms: in at least fifty plant species belonging to ten families,[3] and in at least four animal species, including one gorgonian[17] and three mammalian species.
Another historical milestone is the discovery of DMT in plants frequently used by Amazonian natives as additive to the vine Banisteriopsis caapi to make ayahuasca decoctions. In 1957, American chemists Francis Hochstein and Anita Paradies identified DMT in an "aqueous extract" of leaves of a plant they named Prestonia amazonicum (sic) and described as "commonly mixed" with B. caapi.[18] The lack of a proper botanical identification of Prestonia amazonica in this study led American ethnobotanist Richard Evans Schultes (1915–2001) and other scientists to raise serious doubts about the claimed plant identity.[19][20] A better evidence is produced in 1965 by French pharmacologist Jacques Poisson who isolated DMT as sole alkaloid from leaves, provided and used by Aguaruna Indians, identified as pertaining to the vine Diplopterys cabrerana (then known as Banisteriopsis rusbyana).[20] Published in 1970, the first identification of DMT in the other commonly used additive[clarification needed] plant Psychotria viridis[12] was made by a team of American researchers led by pharmacologist Ara der Marderosian.[21] Not only did they detect DMT in leaves of P. viridis obtained from Cashinahua Indians, but they also were the first to identify it in a sample of an ayahuasca decoction, prepared by the same Indians.[12]

Biosynthesis[edit]

Biosynthetic pathway for N,N-dimethyltryptamine
Dimethyltryptamine is an indole alkaloid derived from the shikimate pathway. Its biosynthesis is relatively simple and summarized in the picture to the left. In plants, the parent amino acid L-tryptophan is produced endogenously where in animals L-tryptophan is an essential amino acid coming from diet. No matter the source of L-tryptophan, the biosynthesis begins with its decarboxylation by an aromatic amino acid decarboxylase (AADC) enzyme (step 1). The resulting decarboxylated tryptophan analog is tryptamine. Tryptamine then undergoes a transmethylation (step 2): the enzyme indolethylamine-N-methyltransferase (INMT) catalyzes the transfer of a methyl group from cofactor S-adenosyl-methionine (SAM), via nucleophilic attack, to tryptamine. This reaction transforms SAM into S-adenosylhomocysteine (SAH), and gives the intermediate product N-methyltryptamine (NMT).[22][23] NMT is in turn transmethylated by the same process (step 3) to form the end product N,N-dimethyltryptamine. Tryptamine transmethylation is regulated by two products of the reaction: SAH,[6][24][25] and DMT[6][25] were shown ex vivo to be among the most potent inhibitors of rabbit INMT activity.
This transmethylation mechanism has been repeatedly and consistently proven by radiolabeling of SAM methyl group with carbon-14 (14C-CH3)SAM).[6][22][25][26][27]

Evidence in mammals[edit]

Published in Science in 1961, Julius Axelrod found an N-methyltransferase enzyme capable of mediating biotransformation of tryptamine into DMT in a rabbit's lung.[22] This finding initiated a still ongoing scientific interest in endogenous DMT production in humans and other mammals.[23][28] From then on, two major complementary lines of evidence have been investigated: localization and further characterization of the N-methyltransferase enzyme, and analytical studies looking for endogenously produced DMT in body fluids and tissues.[23]
In 2013, researchers first reported DMT in the pineal gland microdialysate of rodents.[29]

INMT[edit]

Before techniques of molecular biology were used to localize indolethylamine N-methyltransferase (INMT),[25][27] characterization and localization went on a par: samples of the biological material where INMT is hypothesized to be active are subject to enzyme assay. Those enzyme assays are performed either with a radiolabeled methyl donor like (14C-CH3)SAM to which known amounts of unlabeled substrates like tryptamine are added,[23] or with addition of a radiolabeled substrate like (14C)NMT to demonstrate in vivo formation.[6][26] As qualitative determination of the radioactively tagged product of the enzymatic reaction is sufficient to characterize INMT existence and activity (or lack of), analytical methods used in INMT assays aren't required to be as sensitive as those needed to directly detect and quantify the minute amounts of endogenously formed DMT (see DMT subsection below). The essentially qualitative method thin layer chromatography (TLC) was thus used in a vast majority of studies.[23] Also, robust evidence that INMT can catalyze transmethylation of tryptamine into NMT and DMT could be provided with reverse isotope dilution analysis coupled to mass spectrometry for rabbit[30][31] and human[32] lung during the early 1970s.
Selectivity rather than sensitivity proved to be an Achilles’ heel for some TLC methods with the discovery in 1974–1975 that incubating rat blood cells or brain tissue with (14C-CH3)SAM and NMT as substrate mostly yields tetrahydro-β-carboline derivatives,[6][23][33] and negligible amounts of DMT in brain tissue.[23] It is indeed simultaneously realized that the TLC methods used thus far in almost all published studies on INMT and DMT biosynthesis are incapable to resolve DMT from those tetrahydro-β-carbolines.[23] These findings are a blow for all previous claims of evidence of INMT activity and DMT biosynthesis in avian[34] and mammalian brain,[35][36] including in vivo,[37][38] as they all relied upon use of the problematic TLC methods:[23] their validity is doubted in replication studies that make use of improved TLC methods, and fail to evidence DMT-producing INMT activity in rat and human brain tissues.[39][40] Published in 1978, the last study attempting to evidence in vivo INMT activity and DMT production in brain (rat) with TLC methods finds biotransformation of radiolabeled tryptamine into DMT to be real but "insignificant".[41] Capability of the method used in this latter study to resolve DMT from tetrahydro-β-carbolines is questioned later.[6]
To localize INMT, a qualitative leap is accomplished with use of modern techniques of molecular biology, and of immunohistochemistry. In humans, a gene encoding INMT is determined to be located on chromosome 7.[27] Northern blot analyses reveal INMT messenger RNA (mRNA) to be highly expressed in rabbit lung,[25] and in human thyroid, adrenal gland, and lung.[27][42] Intermediate levels of expression are found in human heart, skeletal muscle, trachea, stomach, small intestine, pancreas, testis, prostate, placenta, lymph node, and spinal cord.[27][42] Low to very low levels of expression are noted in rabbit brain,[27] and human thymus, liver, spleen, kidney, colon, ovary, and bone marrow.[27][42] INMT mRNA expression is absent in human peripheral blood leukocytes, whole brain, and in tissue from 7 specific brain regions (thalamus, subthalamic nucleus, caudate nucleus, hippocampus, amygdala, substantia nigra, and corpus callosum).[27][42] Immunohistochemistry showed INMT to be present in large amounts in glandular epithelial cells of small and large intestines, and to be absent in neurons.[28]

Endogenous DMT[edit]

The first claimed detection of mammalian endogenous DMT was published in June 1965: German researchers F. Franzen and H. Gross report to have evidenced and quantified DMT, along with its structural analog bufotenin (5-OH-DMT), in human blood and urine.[43] In an article published four months later, the method used in their study is strongly criticized, and credibility of their results challenged.[44]
A 2013 study found DMT in microdialysate obtained from a rat's pineal gland, providing evidence of endogenous DMT in the mammalian brain.[29]
In 2001, surveys, made in research articles, point that few of the analytical methods previously used to measure levels of endogenously formed DMT had enough sensitivity and selectivity to produce reliable results.[45][46] Gas chromatography, preferably coupled to mass spectrometry (GC-MS), is considered a minimum requirement.[46] A study published in 2005[28] implements the most sensitive and selective method ever used to measure endogenous DMT:[47] liquid chromatography-tandem mass spectrometry with electrospray ionization (LC-ESI-MS/MS) allows to reach limits of detection (LODs) 12 to 200 fold lower (that is, better) than those attained by the best methods employed in the 1970s. The data summarized in the table below are from studies conforming to the abovementioned requirements (abbreviations used: CSF = cerebrospinal fluid; LOD = limit of detection; n = number of samples; ng/L and ng/kg = nanograms (10−9 g) per litre, and nanograms per kilogram, respectively):
DMT in body fluids and tissues (NB: units have been harmonized)
SpeciesSampleResults
HumanBlood serum< LOD (n = 66)[28]
Blood plasma< LOD (n = 71)[28]  ♦  < LOD (n = 38); 1,000 & 10,600 ng/L (n = 2)[48]
Whole blood< LOD (n = 20); 50–790 ng/L (n = 20)[49]
Urine< 100 ng/L (n = 9)[28]  ♦  < LOD (n = 60); 160–540 ng/L (n = 5)[46]  ♦  Detected in n = 10 by GC-MS[50]
Feces< 50 ng/kg (n = 12); 130 ng/kg (n = 1)[28]
Kidney15 ng/kg (n = 1)[28]
Lung14 ng/kg (n = 1)[28]
Lumbar CSF100,370 ng/L (n = 1); 2,330–7,210 ng/L (n = 3); 350 & 850 ng/L (n = 2)[51]
RatKidney12 &16 ng/kg (n = 2)[28]
Lung22 & 12 ng/kg (n = 2)[28]
Liver6 & 10 ng/kg (n = 2)[28]
Brain10 &15 ng/kg (n = 2)[28]  ♦  Measured in synaptic vesicular fraction[52]
RabbitLiver< 10 ng/kg (n = 1)[28]

Physical and chemical properties[edit]

DMT crystals
DMT is commonly handled and stored as a fumarate,[citation needed] as other DMT acid salts are generally very hygroscopic and will not readily crystallize. Its freebase form, although less stable than DMT fumarate, is favored by recreational users choosing to vaporize the chemical because it has a lower boiling point.[citation needed] In contrast to DMT's base, its salts are water-soluble. DMT in solution degrades relatively quickly and should be stored protected from air, light, and heat in a freezer.[citation needed]

Pharmacology[edit]

Pharmacokinetics[edit]

DMT peak level concentrations (Cmax) measured in whole blood after intramuscular (IM) injection (0.7 mg/kg, n = 11)[53] and in plasma following intravenous (IV) administration (0.4 mg/kg, n = 10)[54] of fully psychedelic doses are in the range of ≈14 to 154 μg/L and 32 to 204 μg/L, respectively. The corresponding molar concentrations of DMT are therefore in the range of 0.074–0.818 µM in whole blood and 0.170–1.08 µM in plasma. However, several studies have described active transport and accumulation of DMT into rat and dog brain following peripheral administration.[55][56][57][58][59] Similar active transport, and accumulation processes likely occur in human brain and may concentrate DMT in brain by several-fold or more (relatively to blood), resulting in local concentrations in the micromolar or higher range. Such concentrations would be commensurate with serotonin brain tissue concentrations which have been consistently determined to be in the 1.5-4 μM range.[60][61]
Closely coextending with peak psychedelic effects, mean time to reach peak concentrations (Tmax) was determined to be 10–15 minutes in whole blood after IM injection,[53] and 2 minutes in plasma after IV administration.[54] When taken orally mixed in an ayahuasca decoction, and in freeze-dried ayahuasca gel caps, DMT Tmax is considerably delayed: 107.59 ± 32.5 minutes,[62] and 90–120 minutes,[63] respectively. The pharmacokinetics for vaporizing DMT have not been studied or reported.

Pharmacodynamics[edit]

DMT binds non-selectively with affinities < 0.6 μM to the following serotonin receptors: 5-HT1A,[64][65][66] 5-HT1B,[64][67] 5-HT1D,[64][66][67] 5-HT2A,[64][66][67][68] 5-HT2B,[64][67] 5-HT2C,[64][67][68] 5-HT6,[64][67] and 5-HT7.[64][67] An agonist action has been determined at 5-HT1A,[65] 5-HT2A and 5-HT2C.[64][67][68] Its efficacies at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT2B receptor as two in vitro assays evidenced DMT high affinity for this receptor: 0.108 μM[67] and 0.184 μM.[64] This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT2B receptor have been causally linked to valvular heart disease.[69][70][71]
It has also been shown to possess affinity for the dopamine D1, α1-adrenergic, α2-adrenergic, imidazoline-1, sigma-1 (σ1), and trace amine-associated receptors.[5][66][67] Agonism was demonstrated at 1 μM at the rat trace amine-associated receptor 1 (TAAR1)[72] and converging lines of evidence established activation of the σ1 receptor at concentrations of 50–100 μM.[73] Its efficacies at the other receptor binding sites are unclear. It has also been shown in vitro to be a substrate for the cell-surface serotonin transporter (SERT) and the intracellular vesicular monoamine transporter 2 (VMAT2), inhibiting SERT-mediated serotonin uptake in human platelets at an average concentration of 4.00 ± 0.70 μM and VMAT2-mediated serotonin uptake in vesicles (of army worm Sf9 cells) expressing rat VMAT-2 at an average concentration of 93 ± 6.8 μM.[74]
As with other so-called "classical hallucinogens",[75] a large part of DMT psychedelic effects can be attributed to a functionally selective activation of the 5-HT2A receptor.[54][64][76][77][78][79][80] DMT concentrations eliciting 50% of its maximal effect (half maximal effective concentration = EC50 or Kact) at the human 5-HT2A receptor in vitro are in the 0.118–0.983 μM range.[64][67][68][81] This range of values coincides well with the range of concentrations measured in blood and plasma after administration of a fully psychedelic dose (see Pharmacokinetics).
As DMT has been shown to have slightly better efficacy (EC50) at human serotonin 2C receptor than at 2A receptor,[67][68] 5-HT2C highly likely also is implicated in DMT's overall effects.[77][82] Other receptors, such as 5-HT1A[66][77][79] σ1,[73][83] and TAAR1[72][84][85] may also play a role.
In 2009 it was hypothesized that DMT may be an endogenous ligand for the σ1 receptor.[73][83] The concentration of DMT needed for σ1 activation in vitro (50–100 μM) is similar to the behaviorally active concentration measured in mouse brain of approximately 106 μM [86] This is minimally 4 orders of magnitude (104) higher than the average concentrations measured in rat brain tissue or human plasma under basal conditions (see Endogenous DMT), so σ1 receptors are likely to be activated only under conditions of high local DMT concentrations. If DMT is stored in synaptic vesicles,[74] such concentrations might occur during vesicular release. To illustrate, while the average concentration of serotonin in brain tissue is in the 1.5-4 μM range,[60][61] the concentration of serotonin in synaptic vesicles was measured at 270 mM.[87] Following vesicular release, the resulting concentration of serotonin in the synaptic cleft, to which serotonin receptors are exposed, is estimated to be about 300 μM. Thus, while in vitro receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects.

Psychedelic properties[edit]

"So I did it and...there was a something, like a flower, like a chrysanthemum in orange and yellow that was sort of spinning, spinning, and then it was like I was pushed from behind and I fell through the chrysanthemum into another place that didn't seem like a state of mind, it seemed like another place. And what was going on in this place aside from the tastefully soffited indirect lighting, and the crawling geometric hallucinations along the domed walls, what was happening was that there were a lot of beings in there, what I call self-transforming machine elves. Sort of like jewelled basketballs all dribbling their way toward me. And if they'd had faces they would have been grinning, but they didn't have faces. And they assured me that they loved me and they told me not to be amazed; not to give way to astonishment."
— Terence McKenna, on his first experience with DMT[88]
DMT is produced naturally in many species of plants often in conjunction with its close chemical relatives 5-MeO-DMT and bufotenin (5-OH-DMT).[89] DMT-containing plants are commonly used in South American Shamanic practices. It is usually one of the main active constituents of the drink ayahuasca,[90][91] however ayahuasca is sometimes brewed with plants which don't produce DMT. It occurs as the primary psychoactive alkaloid in several plants including Mimosa tenuiflora, Diplopterys cabrerana, and Psychotria viridis. DMT is found as a minor alkaloid in snuff made from Virola bark resin in which 5-MeO-DMT is the main active alkaloid.[89] DMT is also found as a minor alkaloid in bark, pods, and beans of Anadenanthera peregrina and Anadenanthera colubrina used to make Yopo and Vilca snuff in which bufotenin is the main active alkaloid.[89][92] Psilocin, an active chemical in many psychedelic mushrooms, is structurally similar to DMT.
The psychotropic effects of DMT were first studied scientifically by the Hungarian chemist and psychologist Dr. Stephen Szára who performed research with volunteers in the mid-1950s. Szára, who later worked for the US National Institutes of Health, had turned his attention to DMT after his order for LSD from the Swiss company Sandoz Laboratories was rejected on the grounds that the powerful psychotropic could be dangerous in the hands of a communist country.[13]
DMT during various stages of purification
DMT can produce powerful psychedelic experiences including intense visuals, euphoria and hallucinations.[8] DMT is generally not active orally unless it is combined with a monoamine oxidase inhibitor (MAOI) such as a reversible inhibitor of monoamine oxidase A (RIMA), for example, harmaline.[9] Without an MAOI, the body quickly metabolizes orally administered DMT, and it therefore has no hallucinogenic effect unless the dose exceeds monoamine oxidase's metabolic capacity. Other means of ingestion such as vaporizing, injecting, or insufflating the drug can produce powerful hallucinations and entheogenic activity for a short time (usually less than half an hour), as the DMT reaches the brain before it can be metabolized by the body's natural monoamine oxidase. Taking a MAOI prior to vaporizing or injecting DMT prolongs and potentiates the effects.[8]

Inhalation[edit]

A standard dose for vaporized DMT is between 15–60 mg. This is generally inhaled in a few successive breaths. The effects last for a short period of time, usually 5 to 15 minutes, dependent on the dose. The onset after inhalation is very fast (less than 45 seconds) and peak effects are reached within a minute. In the 1960s, DMT was known as a "businessman's lunch" in the US because of the relatively short duration (and rapid onset) of action when inhaled.[93]

Insufflation[edit]

Insufflating DMT (commonly as a freebase or fumarate) requires a higher dose than inhalation. The duration is markedly increased, and some users report diminished euphoria but an intensified otherworldly experience. A dose of approximately 70 to 120 mg of insufflated DMT will induce medium to strong effects. If successful in containing this pain-inducing insufflation, the trip can last anywhere from 20 to 50 minutes, with undefinable peak(s).

Injection[edit]

Injected DMT produces an experience that is similar to inhalation in duration, intensity, and characteristics.
In a study conducted from 1990 through 1995, University of New Mexico psychiatrist Rick Strassman found that some volunteers injected with high doses of DMT reported experiences with perceived alien entities. Usually, the reported entities were experienced as the inhabitants of a perceived independent reality the subjects reported visiting while under the influence of DMT.[13] In a September 2009 interview with Examiner.com, Strassman described the effects on participants in the study: "Subjectively, the most interesting results were that high doses of DMT seemed to allow the consciousness of our volunteers to enter into non-corporeal, free-standing, independent realms of existence inhabited by beings of light who oftentimes were expecting the volunteers, and with whom the volunteers interacted. While 'typical' near-death and mystical states occurred, they were relatively rare."

Oral ingestion[edit]

DMT is broken down by the digestive enzyme monoamine oxidase through a process called deamination, and is therefore inactive if taken orally unless combined with a monoamine oxidase inhibitor (MAOI).[9] The traditional South American beverage ayahuasca, or yage, is derived by boiling the ayahuasca vine (Banisteriopsis caapi) with leaves of one or more plants containing DMT, such as Psychotria viridis, Psychotria carthagenensis, or Diplopterys cabrerana.[9] The Ayahuasca vine contains harmala alkaloids,[94] highly active reversible inihibitors of monoamine oxidase A (RIMAs),[95] rendering the DMT orally active by protecting it from deamination.[9] A variety of different recipes are used to make the brew depending on the purpose of the ayahuasca session,[96] or local availability of ingredients. Two common sources of DMT in the western US are reed canary grass (Phalaris arundinacea) and Harding grass (Phalaris aquatica). These invasive grasses contain low levels of DMT and other alkaloids. In addition, Jurema (Mimosa tenuiflora) shows evidence of DMT content: the pink layer in the inner rootbark of this small tree contains a high concentration of N,N-DMT.[citation needed]
Taken orally with an RIMA, DMT produces a long lasting (over 3 hour), slow, deep metaphysical experience similar to that of psilocybin mushrooms, but more intense.[7] RIMAs should be used with caution as they can have lethal complications with some prescription drugs such as SSRI antidepressants, and some over-the-counter drugs.[94]
Induced DMT experiences can include profound time-dilation, visual and auditory illusions, and other experiences that, by most firsthand accounts, defy verbal or visual description. Some users report intense erotic imagery and sensations and utilize the drug in a ritual sexual context.[7][97][98]

Distinguish from 5-MeO-DMT[edit]

5-MeO-DMT, a psychedelic drug structurally similar to N,N-DMT, is sometimes referred to as DMT through abbreviation. As a white, crystalline solid, it is also similar in appearance to DMT. However, it is considerably more potent (5-MeO-DMT typical vaporized dose: 5–20 mg), and care should be taken to clearly differentiate between the two drugs to avoid accidental overdose.[99]

Detection in body fluids[edit]

DMT may be quantitated in blood, plasma or urine using chromatographic techniques as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths. Blood or plasma DMT levels in recreational users of the drug are generally in the 10–30 μg/L range during the first several hours post-ingestion.[citation needed] Less than 0.1% of an oral dose is eliminated unchanged in the 24-hour urine of humans.[100][101]

Side effects[edit]

According to a "Dose-response study of N,N-dimethyltryptamine in humans" by Rick Strassman, "Dimethyltryptamine dose slightly elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-endorphin, corticotropin, cortisol, and prolactin. Growth hormone blood levels rose equally in response to all doses of DMT, and melatonin levels were unaffected."[54]

Conjecture[edit]

DMT crystal at 400x magnification
Several speculative and yet untested hypotheses suggest that endogenous DMT is produced in the human brain and is involved in certain psychological and neurological states. DMT is naturally occurring in small amounts in rat brain, human cerebrospinal fluid, and other tissues of humans and other mammals.[28][51][52][102] A biochemical mechanism for this was proposed by the medical researcher J. C. Callaway, who suggested in 1988 that DMT might be connected with visual dream phenomena: brain DMT levels would be periodically elevated to induce visual dreaming and possibly other natural states of mind.[103] A new hypothesis proposed is that in addition to being involved in altered states of consciousness, endogenous DMT may be involved in the creation of normal waking states of consciousness. It is proposed that DMT and other endogenous hallucinogens mediate their neurological abilities by acting as neurotransmitters at a sub class of the trace amine receptors; a group of receptors found in the CNS where DMT and other hallucinogens have been shown to have activity. Wallach further proposes that in this way waking consciousness can be thought of as a controlled psychedelic experience. It is when the control of these systems becomes loosened and their behavior no longer correlates with the external world that the altered states arise.[84]
Dr. Rick Strassman, while conducting DMT research in the 1990s at the University of New Mexico, advanced the controversial hypothesis that a massive release of DMT from the pineal gland prior to death or near death was the cause of the near death experience (NDE) phenomenon. Several of his test subjects reported NDE-like audio or visual hallucinations. His explanation for this was the possible lack of panic involved in the clinical setting and possible dosage differences between those administered and those encountered in actual NDE cases. Several subjects also reported contact with "other beings", alien like, insectoid or reptilian in nature, in highly advanced technological environments[13] where the subjects were "carried", "probed", "tested", "manipulated", "dismembered", "taught", "loved" and even "raped" by these "beings". Basing his reasoning on his belief that all the enzymatic material needed to produce DMT is found in the pineal gland (see evidence in mammals), and moreover in substantially greater concentrations than in any other part of the body, Strassman ([13] p. 69) has speculated that DMT is made in the pineal gland. Currently there is no published reliable scientific evidence supporting this hypothesis.
In the 1950s, the endogenous production of psychoactive agents was considered to be a potential explanation for the hallucinatory symptoms of some psychiatric diseases as the transmethylation hypothesis[104] (see also adrenochrome), though this hypothesis does not account for the natural presence of endogenous DMT in otherwise normal humans, rats and other laboratory animals.
In 2011, Nicholas V. Cozzi, of the University of Wisconsin School of Medicine and Public Health, concluded that INMT, an enzyme that may be associated with the biosynthesis of DMT and endogenous hallucinogens, is present in the primate (rhesus macaque) pineal gland, retinal ganglion neurons, and spinal cord.[105] In August 2012, Steven Barker, Ethan McIlHenny, and Rick Strassman, developed a new method to measure the three known endogenous hallucinogens and their major N-oxide metabolites in blood, urine, cerebrospinal fluid, ocular fluid and/or other tissues by using state-of-the-art liquid chromatography-mass spectrometry (LC/MS) equipment. For the first time in history, they were able to detect the DMT-N-oxide metabolite in blood and urine.[106]

Legal status[edit]

International law[edit]

DMT is classified as a Schedule I drug under the UN 1971 Convention on Psychotropic Substances, meaning that use of DMT is supposed to be restricted to scientific research and medical use and international trade in DMT is supposed to be closely monitored. Natural materials containing DMT, including ayahuasca, are explicitly not regulated under the 1971 Psychotropic Convention.[107]

Australia[edit]

Between 2011 and 2012, the Australian Federal Government was considering changes to the Australian Criminal Code that would classify any plants containing any amount of DMT as "controlled plants".[108] DMT itself was already controlled under current laws. The proposed changes included other similar blanket bans for other substances, such as a ban on any and all plants containing Mescaline or Ephedrine. The proposal was not pursued after political embarrassment on realisation that this would make Australia's national flower, Acacia pycnantha (Golden Wattle), illegal. The Therapeutic Goods Administration and federal authority had considered a motion to ban the same, but this was withdrawn in May 2012 (as DMT may still hold potential entheogenic value to native and/or religious peoples).[109]

Canada[edit]

DMT is classified in Canada as a Schedule III drug.

France[edit]

DMT, along with most of its plant sources, is classified in France as a stupéfiant (narcotic).

New Zealand[edit]

DMT is classified in New Zealand as a Class A drug under the Misuse of Drugs Act 1975.[110][111]

United Kingdom[edit]

DMT is classified in the United Kingdom as a Class A drug.

United States[edit]

DMT is classified in the United States as a Schedule I drug under the Controlled Substances Act of 1970.
In December 2004, the Supreme Court lifted a stay, thereby allowing the Brazil-based União do Vegetal (UDV) church to use a decoction containing DMT in their Christmas services that year. This decoction is a tea made from boiled leaves and vines, known as hoasca within the UDV, and ayahuasca in different cultures. In Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal, the Supreme Court heard arguments on November 1, 2005, and unanimously ruled in February 2006 that the U.S. federal government must allow the UDV to import and consume the tea for religious ceremonies under the 1993 Religious Freedom Restoration Act.
In September 2008, the three Santo Daime churches filed suit in federal court to gain legal status to import DMT-containing ayahuasca tea. The case, Church of the Holy Light of the Queen v. Mukasey,[112] presided over by Judge Owen M. Panner, was ruled in favor of the Santo Daime church. As of March 21, 2009, a federal judge says members of the church in Ashland can import, distribute and brew ayahuasca. U.S. District Judge Owen Panner issued a permanent injunction barring the government from prohibiting or penalizing the sacramental use of "Daime tea". Panner's order said activities of The Church of the Holy Light of the Queen are legal and protected under freedom of religion. His order prohibits the federal government from interfering with and prosecuting church members who follow a list of regulations set out in his order.[113]

Culture[edit]

In South America, there are a number of indigenous traditions and more recent religious movements based on the use of ayahuasca, usually in an animistic context that may be mixed with Christian imagery. There are three main groups using DMT-MAOI based sacraments in South America.
The Amazon Basin's indigenous population
There are many indigenous cultures in South America, mostly in the Upper Amazon Basin whose traditional religious practices include the use of ayahuasca. These are the oldest cultures in the whole of South America that continue to use ayahuasca or analogue brews, such as the ones made from Jurema in the Pernambuco, near Recife or Iquitos in Peru.
Santo Daime ("Holy Give Unto Me") and Barquinha ("Little Boat")
A syncretic religion from Brazil. The former was founded by Raimundo Irineu Serra in the early 1930s, as an esoteric Christian religion with shamanic tendencies. The Barquinha was derived from this one. The Santo Daime also includes children in their Entheogenic rituals; studies done by the Brazilian government concluded that there were no physical or mental damage caused by this practice, so it is allowed.
União do Vegetal ("Union of the Plants" or UDV)
Another Christian ayahuasca religion from Brazil, a single unified organization with a structure resembling Freemasonry.

Popular culture[edit]

DMT was the subject of a 2010 American documentary titled DMT: The Spirit Molecule.[114] DMT was one of the psychedelic drugs used in the 2009 French movie, titled Enter The Void.[115]

See also[edit]

References[edit]

  1. Jump up ^ Häfelinger, G.; Nimtz, M.; Horstmann, V.; Benz, T. (1999). "Untersuchungen zur Trifluoracetylierung der Methylderivate von Tryptamin und Serotonin mit verschiedenen Derivatisierungsreagentien: Synthesen, Spektroskopie sowie analytische Trennungen mittels Kapillar-GC" [Trifluoracetylation of methylated derivatives of tryptamine and serotonin by different reagents: synthesis, spectroscopic characterizations, and separations by capillary-gas-chromatography]. Zeitschrift für Naturforschung B 54 (3): 397–414. 
  2. Jump up ^ Corothie, E; Nakano, T (1969). "Constituents of the bark of Virola sebifera". Planta Medica 17 (2): 184–188. doi:10.1055/s-0028-1099844. PMID 5792479. 
  3. ^ Jump up to: a b Ott, Jonathan (1994). Ayahuasca Analogues: Pangæan Entheogens (1st ed.). Kennewick, WA, USA: Natural Products. pp. 81–3. ISBN 978-0-9614234-5-2. OCLC 32895480. 
  4. Jump up ^ Shulgin, Alexander; Shulgin, Ann (1997). "DMT is Everywhere". TiHKAL: The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 247–84. ISBN 978-0-9630096-9-2. OCLC 38503252. Retrieved 9 May 2012. 
  5. ^ Jump up to: a b Burchett, Scott A.; Hicks, T. Philip (August 2006). "The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain" (PDF). Progress in Neurobiology 79 (5–6): 223–46. doi:10.1016/j.pneurobio.2006.07.003. ISSN 0301-0082. OCLC 231983957. PMID 16962229. Retrieved 9 May 2012. 
  6. ^ Jump up to: a b c d e f g Barker S.A., Monti J.A., Christian S.T. (1981). "N, N-dimethyltryptamine: an endogenous hallucinogen". International Review of Neurobiology. International Review of Neurobiology 22: 83–110. doi:10.1016/S0074-7742(08)60291-3. ISBN 978-0-12-366822-6. PMID 6792104. 
  7. ^ Jump up to: a b c Salak, Kira. "Hell and back". National Geographic Adventure. 
  8. ^ Jump up to: a b c "Erowid DMT (Dimethyltryptamine) Vault". Erowid.org. Retrieved 2012-09-20. 
  9. ^ Jump up to: a b c d e McKenna, Dennis J.; Towers, G.H.N.; Abbott, F. (April 1984). "Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca". Journal of Ethnopharmacology 10 (2): 195–223. doi:10.1016/0378-8741(84)90003-5. ISSN 0378-8741. PMID 6587171. 
  10. Jump up ^ Manske R.H.F. (1931). "A synthesis of the methyltryptamines and some derivatives". Canadian Journal of Research 5 (5): 592–600. doi:10.1139/cjr31-097. 
  11. ^ Jump up to: a b Bigwood J., Ott J. (November 1977). "DMT: the fifteen minute trip". Head 2 (4): 56–61. Archived from the original on 2006-01-27. Retrieved 2010-11-28. 
  12. ^ Jump up to: a b c Ott, Jonathan (1996). Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History (2nd, densified ed.). Kennewick, WA: Natural Products. ISBN 978-0-9614234-9-0. 
  13. ^ Jump up to: a b c d e Strassman, Rick J. (2001). DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Rochester, Vt: Park Street. ISBN 978-0-89281-927-0.  ("Chapter summaries". Retrieved 27 February 2012. )
  14. ^ Jump up to: a b c Ott, Jonathan (1998). "Pharmahuasca, anahuasca and vinho da jurema: human pharmacology of oral DMT plus harmine". In Müller-Ebeling, C. Special: Psychoactivity. Yearbook for Ethnomedicine and the Study of Consciousness. 6/7 (1997/1998). Berlin: VWB. ISBN 3-86135-033-5. 
  15. Jump up ^ Pachter I.J., Zacharias D.E., Ribeiro O. (September 1959). "Indole alkaloids of Acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis". Journal of Organic Chemistry 24 (9): 1285–87. doi:10.1021/jo01091a032. 
  16. Jump up ^ Fish M.S., Johnson N.M., Horning E.C. (November 1955). "Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species". Journal of the American Chemical Society 72 (22): 5892–95. doi:10.1021/ja01627a034. 
  17. Jump up ^ Cimino G., De Stefano S. (1978). "Chemistry of Mediterranean gorgonians: simple indole derivatives from Paramuricea chamaeleon". Comparative Biochemistry and Physiology Part C: Comparative Pharmacology 61 (2): 361–2. doi:10.1016/0306-4492(78)90070-9. 
  18. Jump up ^ Hochstein F.A., Paradies A.M. (1957). "Alkaloids of Banisteria caapi and Prestonia amazonicum". Journal of the American Chemical Society 79 (21): 5735–36. doi:10.1021/ja01578a041. 
  19. Jump up ^ Schultes R.E., Raffauf R.F. (1960). "Prestonia: An Amazon narcotic or not?". Botanical Museum Leaflets, Harvard University 19 (5): 109–122. ISSN 0006-8098. 
  20. ^ Jump up to: a b Poisson J. (April 1965). "Note sur le "Natem", boisson toxique péruvienne et ses alcaloïdes" [Note on "Natem", a toxic Peruvian beverage, and its alkaloids]. Annales Pharmaceutiques Françaises (in French) 23: 241–4. ISSN 0003-4509. PMID 14337385. 
  21. Jump up ^ Der Marderosian A.H., Kensinger K.M., Chao J.-M., Goldstein F.J. (1970). "The use and hallucinatory principles of a psychoactive beverage of the Cashinahua tribe (Amazon basin)". Drug Dependence 5: 7–14. ISSN 0070-7368. OCLC 1566975. 
  22. ^ Jump up to: a b c Axelrod J. (August 1961). "Enzymatic formation of psychotomimetic metabolites from normally occurring compounds". Science 134 (3475): 343. doi:10.1126/science.134.3475.343. PMID 13685339. 
  23. ^ Jump up to: a b c d e f g h i Rosengarten H., Friedhoff A.J. (1976). "A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances" (PDF). Schizophrenia Bulletin 2 (1): 90–105. doi:10.1093/schbul/2.1.90. PMID 779022. 
  24. Jump up ^ Lin R.L., Narasimhachari N., Himwich H.E. (September 1973). "Inhibition of indolethylamine-N-methyltransferase by S-adenosylhomocysteine". Biochemical and Biophysical Research Communications 54 (2): 751–9. doi:10.1016/0006-291X(73)91487-3. PMID 4756800. 
  25. ^ Jump up to: a b c d e Thompson M.A., Weinshilboum R.M. (December 1998). "Rabbit lung indolethylamine N-methyltransferase. cDNA and gene cloning and characterization". Journal of Biological Chemistry 273 (51): 34502–10. doi:10.1074/jbc.273.51.34502. PMID 9852119. Retrieved 2010-11-09. 
  26. ^ Jump up to: a b Mandel L.R., Prasad R., Lopez-Ramos B., Walker R.W. (January 1977). "The biosynthesis of dimethyltryptamine in vivo". Research Communications in Chemical Pathology and Pharmacology 16 (1): 47–58. PMID 14361. 
  27. ^ Jump up to: a b c d e f g h Thompson M.A., Moon E., Kim U.J., Xu J., Siciliano M.J., Weinshilboum R.M. (November 1999). "Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization" (PDF). Genomics 61 (3): 285–97. doi:10.1006/geno.1999.5960. PMID 10552930. 
  28. ^ Jump up to: a b c d e f g h i j k l m n o Kärkkäinen J., Forsström T., Tornaeus J., Wähälä K., Kiuru P., Honkanen A., Stenman U.-H., Turpeinen U., Hesso A. (April 2005). "Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues". Scandinavian Journal of Clinical and Laboratory Investigation 65 (3): 189–199. doi:10.1080/00365510510013604. PMID 16095048. 
  29. ^ Jump up to: a b Barker SA, Borjigin J, Lomnicka I, Strassman R (Jul 2013). "LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate". Biomed Chromatogr. doi:10.1002/bmc.2981. PMID 23881860. 
  30. Jump up ^ Mandel L.R., Rosenzweig S., Kuehl F.A. (March 1971). "Purification and substrate specificity of indoleamine-N-methyl transferase". Biochemical Pharmacology 20 (3): 712–6. doi:10.1016/0006-2952(71)90158-4. PMID 5150167. 
  31. Jump up ^ Lin R.-L., Narasimhachari N. (June 1975). "N-methylation of 1-methyltryptamines by indolethylamine N-methyltransferase". Biochemical Pharmacology 24 (11–12): 1239–40. doi:10.1016/0006-2952(75)90071-4. PMID 1056183. 
  32. Jump up ^ Mandel L.R., Ahn H.S., VandenHeuvel W.J. (April 1972). "Indoleamine-N-methyl transferase in human lung". Biochemical Pharmacology 21 (8): 1197–200. doi:10.1016/0006-2952(72)90113-X. PMID 5034200. 
  33. Jump up ^ Rosengarten H., Meller E., Friedhoff A.J. (1976). "Possible source of error in studies of enzymatic formation of dimethyltryptamine". Journal of Psychiatric Research 13 (1): 23–30. doi:10.1016/0022-3956(76)90006-6. PMID 1067427. 
  34. Jump up ^ Morgan M., Mandell A.J. (August 1969). "Indole(ethyl)amine N-methyltransferase in the brain". Science 165 (3892): 492–3. doi:10.1126/science.165.3892.492. PMID 5793241. 
  35. Jump up ^ Mandell A.J., Morgan M. (March 1971). "Indole(ethyl)amine N-methyltransferase in human brain". Nature: New Biology 230 (11): 85–7. doi:10.1038/newbio230085a0. PMID 5279043. 
  36. Jump up ^ Saavedra J.M., Coyle J.T., Axelrod J. (March 1973). "The distribution and properties of the nonspecific N-methyltransferase in brain". Journal of Neurochemistry 20 (3): 743–52. doi:10.1111/j.1471-4159.1973.tb00035.x. PMID 4703789. 
  37. Jump up ^ Saavedra J.M., Axelrod J. (March 1972). "Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro" (PDF). Science 175 (4028): 1365–6. doi:10.1126/science.175.4028.1365. PMID 5059565. 
  38. Jump up ^ Wu P.H., Boulton A.A. (July 1973). "Distribution and metabolism of tryptamine in rat brain". Canadian Journal of Biochemistry 51 (7): 1104–12. doi:10.1139/o73-144. PMID 4725358. 
  39. Jump up ^ Boarder M.R., Rodnight R. (September 1976). "Tryptamine-N-methyltransferase activity in brain tissue: a re-examination". Brain Research 114 (2): 359–64. doi:10.1016/0006-8993(76)90680-6. PMID 963555. 
  40. Jump up ^ Gomes U.R., Neethling A.C., Shanley B.C. (September 1976). "Enzymatic N-methylation of indoleamines by mammalian brain: fact or artefact?". Journal of Neurochemistry 27 (3): 701–5. doi:10.1111/j.1471-4159.1976.tb10397.x. PMID 823298. 
  41. Jump up ^ Stramentinoli G., Baldessarini R.J. (October 1978). "Lack of enhancement of dimethyltryptamine formation in rat brain and rabbit lung in vivo by methionine or S-adenosylmethionine". Journal of Neurochemistry 31 (4): 1015–20. doi:10.1111/j.1471-4159.1978.tb00141.x. PMID 279646. 
  42. ^ Jump up to: a b c d General annotation of Human INMT (O95050) entry in UniProtKB/Swiss-Prot
  43. Jump up ^ Franzen F., Gross H. (June 1965). "Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine". Nature 206 (988): 1052. doi:10.1038/2061052a0. PMID 5839067. "After the elaboration of sufficiently selective and quantitative procedures, which are discussed elsewhere, we were able to study the occurrence of tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-hydroxytryptamine in normal human blood and urine. (...) In 11 of 37 probands N,N-dimethyltryptamine was demonstrated in blood (...). In the urine 42·95 ± 8·6 μg of dimethyltryptamine/24 h were excreted." 
  44. Jump up ^ Siegel M. (October 1965). "A sensitive method for the detection of N,N-dimethylserotonin (bufotenin) in urine; failure to demonstrate its presence in the urine of schizophrenic and normal subjects". Journal of Psychiatric Research 3 (3): 205–11. doi:10.1016/0022-3956(65)90030-0. PMID 5860629. 
  45. Jump up ^ Barker S.A., Littlefield-Chabaud M.A., David C. (February 2001). "Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method". Journal of Chromatography B 751 (1): 37–47. doi:10.1016/S0378-4347(00)00442-4. PMID 11232854. 
  46. ^ Jump up to: a b c Forsström T., Tuominen J., Karkkäinen J. (2001). "Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS". Scandinavian Journal of Clinical and Laboratory Investigation 61 (7): 547–56. doi:10.1080/003655101753218319. PMID 11763413. 
  47. Jump up ^ Shen H.W., Jiang X.L., Yu A.M. (April 2009). "Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study". Bioanalysis 1 (1): 87–95. doi:10.4155/bio.09.7. PMC 2879651. PMID 20523750. 
  48. Jump up ^ Wyatt R.J., Mandel L.R., Ahn H.S., Walker R.W., Vanden Heuvel W.J. (July 1973). "Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients" (PDF). Psychopharmacologia 31 (3): 265–70. doi:10.1007/BF00422516. PMID 4517484. 
  49. Jump up ^ Angrist B., Gershon S., Sathananthan G., Walker R.W., Lopez-Ramos B., Mandel L.R., Vandenheuvel W.J. (May 1976). %7CFormat PDF "Dimethyltryptamine levels in blood of schizophrenic patients and control subjects". Psychopharmacology 47 (1): 29–32. doi:10.1007/BF00428697. PMID 803203. 
  50. Jump up ^ Oon M.C., Rodnight R. (December 1977). "A gas chromatographic procedure for determining N, N-dimethyltryptamine and N-monomethyltryptamine in urine using a nitrogen detector". Biochemical Medicine 18 (3): 410–9. doi:10.1016/0006-2944(77)90077-1. PMID 271509. 
  51. ^ Jump up to: a b Smythies J.R., Morin R.D., Brown G.B. (June 1979). "Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry". Biological Psychiatry 14 (3): 549–56. PMID 289421. 
  52. ^ Jump up to: a b Christian S.T., Harrison R., Quayle E., Pagel J., Monti J. (October 1977). "The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent". Biochemical Medicine 18 (2): 164–83. doi:10.1016/0006-2944(77)90088-6. PMID 20877. 
  53. ^ Jump up to: a b Kaplan J., Mandel L.R., Stillman R., Walker R.W., VandenHeuvel W.J., Gillin J.C., Wyatt R.J. (1974). "Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects" (PDF). Psychopharmacologia 38 (3): 239–45. doi:10.1007/BF00421376. PMID 4607811. 
  54. ^ Jump up to: a b c d Strassman R.J., Qualls C.R. (February 1994). "Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects". Archives of General Psychiatry 51 (2): 85–97. doi:10.1001/archpsyc.1994.03950020009001. PMID 8297216. 
  55. Jump up ^ Barker S.A., Beaton J.M., Christian S.T., Monti J.A., Morris P.E. (August 1982). "Comparison of the brain levels of N,N-dimethyltryptamine and α, α, β, β-tetradeutero-N-N-dimethyltryptamine following intraperitoneal injection. The in vivo kinetic isotope effect". Biochemical Pharmacology 31 (15): 2513–6. doi:10.1016/0006-2952(82)90062-4. PMID 6812592. 
  56. Jump up ^ Sangiah S., Gomez M.V., Domino E.F. (December 1979). "Accumulation of N,N-dimethyltryptamine in rat brain cortical slices". Biological Psychiatry 14 (6): 925–36. PMID 41604. 
  57. Jump up ^ Sitaram B.R., Lockett L., Talomsin R., Blackman G.L., McLeod W.R. (May 1987). "In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat". Biochemical Pharmacology 36 (9): 1509–12. doi:10.1016/0006-2952(87)90118-3. PMID 3472526. 
  58. Jump up ^ Takahashi T., Takahashi K., Ido T., Yanai K., Iwata R., Ishiwata K., Nozoe S. (December 1985). "[11C]-labeling of indolealkylamine alkaloids and the comparative study of their tissue distributions". International Journal of Applied Radiation and Isotopes 36 (12): 965–9. doi:10.1016/0020-708X(85)90257-1. PMID 3866749. 
  59. Jump up ^ Yanai K., Ido T., Ishiwata K., Hatazawa J, Takahashi T., Iwata R., Matsuzawa T. (1986). "In vivo kinetics and displacement study of a carbon-11-labeled hallucinogen, N,N-(11C)dimethyltryptamine" (PDF). European Journal of Nuclear Medicine 12 (3): 141–6. doi:10.1007/BF00276707. PMID 3489620. 
  60. ^ Jump up to: a b Best J, Nijhout HF, Reed M (2010). "Serotonin synthesis, release and reuptake in terminals: a mathematical model". Theoretical Biology & Medical Modelling 7: 34. doi:10.1186/1742-4682-7-34. PMC 2942809. PMID 20723248. 
  61. ^ Jump up to: a b Merrill MA, Clough RW, Jobe PC, Browning RA (September 2005). "Brainstem seizure severity regulates forebrain seizure expression in the audiogenic kindling model" (PDF). Epilepsia 46 (9): 1380–8. doi:10.1111/j.1528-1167.2005.39404.x. PMID 16146432. 
  62. Jump up ^ Callaway J.C., McKenna D.J., Grob C.S., Brito G.S., Raymon L.P., Poland R.E., Andrade E.N. et al. (June 1999). "Pharmacokinetics of Hoasca alkaloids in healthy humans" (PDF). Journal of Ethnopharmacology 65 (3): 243–56. doi:10.1016/S0378-8741(98)00168-8. PMID 10404423. 
  63. Jump up ^ Riba J., Valle M., Urbano G., Yritia M., Morte A., Barbanoj M.J. (July 2003). "Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics" (PDF). Journal of Pharmacology and Experimental Therapeutics 306 (1): 73–83. doi:10.1124/jpet.103.049882. PMID 12660312. 
  64. ^ Jump up to: a b c d e f g h i j k l Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., Jensen N.H. et al. (November 2009). "Predicting new molecular targets for known drugs". Nature 462 (7270): 175–81. doi:10.1038/nature08506. PMC 2784146. PMID 19881490. 
  65. ^ Jump up to: a b Deliganis A.V., Pierce P.A., Peroutka S.J. (June 1991). "Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors". Biochemical Pharmacology 41 (11): 1739–44. doi:10.1016/0006-2952(91)90178-8. PMID 1828347. 
  66. ^ Jump up to: a b c d e Pierce P.A., Peroutka S.J. (1989). "Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex" (PDF). Psychopharmacology 97 (1): 118–22. doi:10.1007/BF00443425. PMID 2540505. 
  67. ^ Jump up to: a b c d e f g h i j k l Ray T.S. (2010). "Psychedelics and the Human Receptorome". In Manzoni, Olivier Jacques. PLoS ONE 5 (2): e9019. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400. 
  68. ^ Jump up to: a b c d e Smith R.L., Canton H., Barrett R.J., Sanders-Bush E. (November 1998). "Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors" (PDF). Pharmacology, Biochemistry, and Behavior 61 (3): 323–30. doi:10.1016/S0091-3057(98)00110-5. PMID 9768567. 
  69. Jump up ^ Rothman R.B., Baumann M.H. (May 2009). "Serotonergic Drugs and Valvular Heart Disease" (PDF). Expert Opinion on Drug Safety 8 (3): 317–29. doi:10.1517/14740330902931524. PMC 2695569. PMID 19505264. 
  70. Jump up ^ Roth B.L. (January 2007). "Drugs and valvular heart disease". New England Journal of Medicine 356 (1): 6–9. doi:10.1056/NEJMp068265. PMID 17202450. 
  71. Jump up ^ Jonathan D. Urban, William P. Clarke, Mark von Zastrow, David E. Nichols, Brian Kobilka, Harel Weinstein, Jonathan A. Javitch, Bryan L. Roth, Arthur Christopoulos, Patrick M. Sexton, Keith J. Miller, Michael Spedding and Richard B. Mailman (2006-06-27). "Functional Selectivity and Classical Concepts of Quantitative Pharmacology". JPET 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID 16803859. 
  72. ^ Jump up to: a b Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., Darland T. et al. (2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor" (PDF). Molecular Pharmacology 60 (6): 1181–8. PMID 11723224. 
  73. ^ Jump up to: a b c Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E. (February 2009). "The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator". Science 323 (5916): 934–7. doi:10.1126/science.1166127. PMC 2947205. PMID 19213917. 
  74. ^ Jump up to: a b Cozzi N.V., Gopalakrishnan A., Anderson L.L., Feih J.T., Shulgin A.T., Daley P.F., Ruoho A.E. (December 2009). "Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter" (PDF). Journal of Neural Transmission 116 (12): 1591–9. doi:10.1007/s00702-009-0308-8. PMID 19756361. 
  75. Jump up ^ Glennon, R.A. (1994). "Classical hallucinogens: an introductory overview". In Lin, G.C.; Glennon, R.A. Hallucinogens: An Update. NIDA Research Monograph Series 146. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse. p. 4. 
  76. Jump up ^ Fantegrossi W.E., Murnane K.S., Reissig C.J. (January 2008). "The behavioral pharmacology of hallucinogens" (PDF). Biochemical Pharmacology 75 (1): 17–33. doi:10.1016/j.bcp.2007.07.018. PMC 2247373. PMID 17977517. 
  77. ^ Jump up to: a b c Nichols D.E. (February 2004). "Hallucinogens". Pharmacology & Therapeutics 101 (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703. 
  78. Jump up ^ Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bäbler A., Vogel H., Hell D. (December 1998). "Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action". NeuroReport 9 (17): 3897–902. doi:10.1097/00001756-199812010-00024. PMID 9875725. 
  79. ^ Jump up to: a b Strassman R.J. (1996). "Human psychopharmacology of N,N-dimethyltryptamine" (PDF). Behavioural Brain Research 73 (1–2): 121–4. doi:10.1016/0166-4328(96)00081-2. PMID 8788488. 
  80. Jump up ^ Glennon R.A., Titeler M., McKenney J.D. (December 1984). "Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents". Life Sciences 35 (25): 2505–11. doi:10.1016/0024-3205(84)90436-3. PMID 6513725. 
  81. Jump up ^ Roth B.L., Choudhary M.S., Khan N., Uluer A.Z. (February 1997). "High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model" (PDF). Journal of Pharmacology and Experimental Therapeutics 280 (2): 576–83. PMID 9023266. 
  82. Jump up ^ Canal C.E., Olaghere da Silva U.B., Gresch P.J., Watt E.E., Sanders-Bush E., Airey D.C. (April 2010). "The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen" (PDF). Psychopharmacology 209 (2): 163–74. doi:10.1007/s00213-010-1784-0. PMC 2868321. PMID 20165943. 
  83. ^ Jump up to: a b Su T.P., Hayashi T., Vaupel D.B. (2009). "When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor" (PDF). Science Signaling 2 (61): pe12. doi:10.1126/scisignal.261pe12. PMC 3155724. PMID 19278957. 
  84. ^ Jump up to: a b Wallach J.V. (January 2009). "Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception". Medical Hypotheses 72 (1): 91–4. doi:10.1016/j.mehy.2008.07.052. PMID 18805646. 
  85. Jump up ^ Jacob M.S., Presti D.E. (2005). "Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine" (PDF). Medical Hypotheses 64 (5): 930–7. doi:10.1016/j.mehy.2004.11.005. PMID 15780487. 
  86. Jump up ^ Morinan A., Collier J.G. (1981). "Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice". Psychopharmacology 75 (2): 179–83. doi:10.1007/BF00432184. PMID 6798607. 
  87. Jump up ^ Bruns D., Riedel D., Klingauf J., Jahn R. (October 2000). "Quantal release of serotonin". Neuron 28 (1): 205–20. doi:10.1016/S0896-6273(00)00097-0. PMID 11086995. 
  88. Jump up ^ Alien Dreamtime a multimedia event recorded live. (27 February 1993)
  89. ^ Jump up to: a b c Torres, Constantino Manuel; Repke, David B. (2006). Anadenanthera: Visionary Plant Of Ancient South America. Binghamton, NY: Haworth Herbal. pp. 107–122. ISBN 978-0-7890-2642-2. 
  90. Jump up ^ Rivier, Laurent; Lindgren, Jan-Erik (1972). ""Ayahuasca," the South American hallucinogenic drink: An ethnobotanical and chemical investigation". Economic Botany 26 (2): 101–129. doi:10.1007/BF02860772. ISSN 0013-0001. 
  91. Jump up ^ McKenna, Dennis J.; Towers, G.H.N.; Abbott, F. (1984). "Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca". Journal of Ethnopharmacology 10 (2): 195–223. doi:10.1016/0378-8741(84)90003-5. ISSN 0378-8741. PMID 6587171. 
  92. Jump up ^ Ott J. (2001). "Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine" (PDF). Journal of Psychoactive Drugs 33 (3): 273–81. doi:10.1080/02791072.2001.10400574. PMID 11718320. 
  93. Jump up ^ Haroz, Rachel; Greenberg, Michael I. (November 2005). "Emerging Drugs of Abuse". Medical Clinics of North America (Philadelphia: Saunders) 89 (6): 1259–76. doi:10.1016/j.mcna.2005.06.008. ISSN 0025-7125. OCLC 610327022. PMID 16227062. "Use of DMT was first encountered in the United States in the 1960s, when it was known as a “businessman's lunch” because of the rapid onset of action when smoked (2 to 5 minutes) and short duration of action (20 minutes to 1 hour)." 
  94. ^ Jump up to: a b Callaway, James C.; Grob, Charles S. (1998). "Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions" (PDF). Journal of Psychoactive Drugs 30 (4): 367–9. doi:10.1080/02791072.1998.10399712. ISSN 0279-1072. PMID 9924842. 
  95. Jump up ^ Bergström, Mats; Westerberg, Göran; Långström, Bengt (1997). "11C-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies". Nuclear Medicine and Biology 24 (4): 287–293. doi:10.1016/S0969-8051(97)00013-9. ISSN 0969-8051. PMID 9257326. 
  96. Jump up ^ Andritzky, Walter (1989). "Sociopsychotherapeutic Functions of Ayahuasca Healing in Amazonia". Journal of Psychoactive Drugs 21 (1): 77–89. doi:10.1080/02791072.1989.10472145. ISSN 0279-1072. PMID 2656954. Archived from the original on 26 February 2008. Retrieved 10 April 2012. 
  97. Jump up ^ "2C-B, DMT, You and Me". Maps. Retrieved 2007-01-13. 
  98. Jump up ^ "Entheogens & Visionary Medicine Pages". Miqel.com. Retrieved 2007-08-17. 
  99. Jump up ^ Erowid (14 February 1999). "5-MeO-DMT dosage". Erowid 5-MeO-DMT Vault. Retrieved 8 December 2010. 
  100. Jump up ^ Callaway JC, Raymon LP, Hearn WL, et al. Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca (1996). "Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca". J. Anal. Toxicol. 20 (6): 492–497. doi:10.1093/jat/20.6.492. PMID 8889686. 
  101. Jump up ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 9th edition, Biomedical Publications, Seal Beach, CA, 2011, pp. 525–526.
  102. Jump up ^ "The God Chemical: Brain Chemistry And Mysticism". NPR. Retrieved 2012-09-20. 
  103. Jump up ^ Callaway J (1988). "A proposed mechanism for the visions of dream sleep". Med Hypotheses 26 (2): 119–24. doi:10.1016/0306-9877(88)90064-3. PMID 3412201. 
  104. Jump up ^ Hoffer A., Osmond H., Smythies J. (January 1954). "Schizophrenia; a new approach. II. Result of a year's research". Journal of Mental Science 100 (418): 29–45. doi:10.1192/bjp.100.418.29. PMID 13152519. 
  105. Jump up ^ http://www.neurophys.wisc.edu/~cozzi/Indolethylamine%20N-methyltransferase%20expression%20in%20primate%20nervous%20tissue.pdf
  106. Jump up ^ "DMT Update | Cottonwood Research Foundation, Inc". Cottonwoodresearch.org. 2012-08-13. Retrieved 2012-09-20. 
  107. Jump up ^ Schaepe, Herbert (2001). "International control of the preparation "ayahuasca"" (JPG). Erowid. Retrieved November 29, 2010. 
  108. Jump up ^ "Consultation on implementation of model drug schedules for Commonwealth serious drug offences". Australian Government, Attorney-General’s Department. 24 June 2010. 
  109. Jump up ^ http://connection.ebscohost.com/c/articles/79564875/aussie-dmt-ban
  110. Jump up ^ Berry, Michael; NZPA (19 May 2011). "Rare drug bound for Blenheim". Malborough Express (Blenheim, New Zealand: Fairfax New Zealand). Retrieved 23 May 2012. 
  111. Jump up ^ "Schedule 1: Class A controlled drugs". Misuse of Drugs Act 1975. Wellington, N.Z.: Parliamentary Counsel Office/Te Tari Tohutohu Pāremata. 1 May 2012. Retrieved 23 May 2012. 
  112. Jump up ^ Church of the Holy Light of the Queen v. Mukasey
  113. Jump up ^ Church of the Holy Light of the Queen v. Mukasey (D. Ore. 2009) (“permanently enjoins Defendants from prohibiting or penalizing the sacramental use of Daime tea by Plaintiffs during Plaintiffs' religious ceremonies”). Text
  114. Jump up ^ http://www.imdb.com/title/tt1340425/
  115. Jump up ^ Ryan Lambie (2010-09-21). "Gaspar Noé Interview: Enter The Void, illegal substances and life after death". Den of Geek. Retrieved 2012-09-20. 

External links[edit]

Retrieved from "http://en.wikipedia.org/w/index.php?title=Dimethyltryptamine&oldid=585984426"
at No comments:
Labels: , , , ,
Subscribe to: Comments (Atom)

Reviving the Ancient Polymath Spirit to Meet Modern Challenges We can embrace interdisciplinary learning for innovative problem-solving. Posted January 16, 2025 | Reviewed by Gary Drevitch

  by   Nigel R. Bairstow Ph.D. Disconnection Dynamics Psychology Today Key points Ancient Arab polymaths excelled by integrating diverse kno...